Učitavanje...
PARPi after PARPi in epithelial ovarian cancer
The objective of this study was to describe the treatment experience of patients with recurrent epithelial ovarian cancer who are retreated with an inhibitor of poly(ADP-ribose)-polymerase (PARPi). We conducted a multi-institutional, retrospective review of ovarian cancer patients who received ≥2 li...
Spremljeno u:
| Izdano u: | Gynecol Oncol Rep |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7840844/ https://ncbi.nlm.nih.gov/pubmed/33537389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2021.100699 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|